Gold Nanocrystals May Remyelinate Lesions in Multiple Sclerosis Gold Nanocrystals May Remyelinate Lesions in Multiple Sclerosis
Animals treated with CNM-Au8 had improved motor function, a new study shows. Already shown safe in phase 1 trials, research with this'new therapeutic paradigm'will soon move to phase 2, researchers say.Medscape Medical News
Conor Devine, who was diagnosed with multiple sclerosis in 2007, is fighting back against his illness.
Authors: Joly H, Cohen M, Bresch S, Lebrun-Frenay C PMID: 31221416 [PubMed - as supplied by publisher]
The FDA has recently approved two new oral drugs, cladribine (Mavenclad) and siponimod (Mayzent), to treat multiple sclerosis.
CONCLUSIONS: Cladribine Tablets is a cost-effective treatment, compared to fingolimod, for the treatment of RMS with high disease activity. PMID: 31220959 [PubMed - as supplied by publisher]
Publication date: Available online 20 June 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Kassandra L. Munger, Hilda Dejong, Feng Zhu, Helen Tremlett, Alberto Ascherio
Hello students and future colleagues I wondered if you could help me out with MS What is exactly the meaning of the term "Progression" in MS - pathologically and clinically (guess worsening - greater degree of disability?), as progression in e.g. relapsing-remitting MS; is stated to occur between the attacks/relapses. Thanks for the cooperation
A U.S. group that reviews the value of medicines issued a critical report on Novartis's new multiple sclerosis drug Mayzent, calling its $88,561 list price "far out of line" compared with its benefits for patients.
(Kessler Foundation) Two Kessler Foundation scientists received grants from the New Jersey Health Foundation. Vikram Shenoy Handiru, PhD, received a one-year $35,000 award for his project titled, 'Targeted Noninvasive Brain Stimulation for Improving the Hand Dexterity in Stroke Patients.' Katie Lancaster, PhD, received a one-year $35,000 award for her project titled: 'A Social Emotion Regulation Intervention in Multiple Sclerosis.'
To examine the relationship between perception of multiple sclerosis (MS) impact and treatment efficacy beliefs in patients with MS and the extent to which self and illness appraisals can be regarded as mediator variables in this relationship.
Authors: Baldassari LE, Feng J, Clayton BLL, Oh SH, Sakaie K, Tesar PJ, Wang Y, Cohen JA Abstract Introduction: Approved disease modifying therapies for multiple sclerosis (MS) lessen inflammatory disease activity that causes relapses and MRI lesions. However, chronic inflammation and demyelination lead to axonal degeneration and neuronal loss, for which there currently is no effective treatment. There has been increasing interest in developing repair-promoting strategies, but there are important unanswered questions regarding the mechanisms and appropriate methods to evaluate these treatments. Areas covered: The rati...